On-Body Drug Delivery Devices Market By Device Type (On-Body Injectors, Wearable Infusion Pumps, Patch-Based Delivery Devices); By Delivery Mechanism (Needle-Based Devices, Needle-Free Devices, Pump-Based Devices); By Device Configuration (Disposable Devices, Reusable Devices, Hybrid Devices); By Therapeutic Application (Diabetes, Oncology, Autoimmune Disorders, Cardiovascular Diseases, Neurological Disorders, Other Applications); By End User (Home Care Settings, Hospitals, Specialty Clinics, Ambulatory Care Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

How Are Large-Volume Biologics and Home-Based Care Reshaping the On-Body Drug Delivery Devices Market? – (Updated On: 6th-Oct-2026)

The Global On-Body Drug Delivery Devices Market was valued at USD 421.7 million in 2025 and is projected to reach USD 687.9 million by 2032, expanding at a CAGR of 7.24% during 2026–2032.

 

On-body drug delivery devices are wearable systems that administer medicines subcutaneously over a controlled period. Their strongest commercial role is in large-volume and high-viscosity biologics, where conventional syringes or standard autoinjectors may not be suitable. These platforms can also support treatment outside hospitals and infusion centers, helping pharmaceutical companies move selected therapies toward home-based administration.

 

Several companies are developing platforms around higher dose capacity, reusable electronics, and connected monitoring. Enable Injections’ enFuse supports delivery volumes of up to 50 mL, making it suitable for larger biologic doses. West Pharmaceutical Services’ SmartDose combines wearable administration with a dedicated drug container and automated feedback. Stevanato Group’s Vertiva uses a single-use pod with a reusable smart controller and supports both bolus and continuous basal infusion. Nemera’s Symbioze is designed around a reusable electromechanical module and sterile fluid path for high-viscosity biologics, while BD Evolve is being developed for volumes up to 3 mL.

 

Digital integration is also becoming more important. Bluetooth, NFC, smart controllers, and mobile applications can track injection progress, record administration events, and support adherence monitoring.

 

Therapeutic use is expanding across immunology, autoimmune diseases, oncology, cardiovascular and metabolic disorders, and diabetes management. The market is increasingly favoring platforms that combine flexible dosing, larger drug volumes, patient-friendly operation, and connected functionality within a scalable drug-device system.

 

Which Segments Are Leading and Growing Fastest in the On-Body Drug Delivery Devices Market?

By Device Type: Wearable Formats Bring Large-Volume Therapy Home

Leading Segment – On-Body Injectors

On-Body Injectors account for approximately 46% of the On-Body Drug Delivery Devices Market, representing around USD 194.0 million in 2025, and are projected to expand at a CAGR of 7.00% during 2026–2032. Also known as patch or wearable injectors, these devices automate the subcutaneous delivery of large-volume and high-viscosity medicines. Their ability to administer therapies outside hospitals and clinics supports wider use in home-based care, particularly for biologics and treatments requiring controlled, longer-duration drug administration.

Fastest-Growing Segment – Patch-Based Delivery Devices

Patch-Based Delivery Devices account for approximately 20% of the On-Body Drug Delivery Devices Market, valued at around USD 84.3 million in 2025, and are projected to register the fastest CAGR of 7.70% during 2026–2032. These devices act as the direct skin interface of on-body delivery systems, allowing medicines to be administered in a controlled and continuous manner. Their compact design and patient-friendly administration support wider use for therapies requiring convenient, longer-duration drug delivery.

 

By Delivery Mechanism: Established Needles and the Rise of Needle-Free Systems

Leading Segment – Needle-Based Devices

Needle-Based Devices account for approximately 52% of the On-Body Drug Delivery Devices Market, valued at around USD 219.3 million in 2025 and projected to reach nearly USD 347.6 million by 2032, at a CAGR of 6.80% during 2026–2032. Needle-based systems form the critical connection between the wearable drug reservoir and subcutaneous tissue, allowing controlled administration of large-volume and high-viscosity biologics. Their established use across wearable injectors supports their leading position within on-body drug delivery applications.

Fastest-Growing Segment – Needle-Free Devices

Needle-free systems are emerging as a fast-expanding segment within the On-Body Drug Delivery Devices Market. They account for approximately 14% of the market, valued at around USD 59.0 million in 2025, and are projected to expand at a CAGR of 9.20% during 2026–2032. Instead of conventional hypodermic needles, these systems use high-pressure jets, springs, gas propulsion, or Lorentz-force technology to deliver liquid or powdered medicines through the skin, supporting more convenient on-body administration.

 

By Device Configuration: Disposable Scale Meets Reusable and Hybrid Designs

Leading Segment – Disposable Devices

Disposable Devices hold approximately 55% of the On-Body Drug Delivery Devices Market, representing around USD 231.9 million in 2025, and are projected to expand at a CAGR of 6.60% during 2026–2032. Disposable components form the patient-contact portion of on-body drug delivery systems, managing direct drug contact, fluid pathways, and skin interaction while remaining separate from reusable electronic activators. Their single-use design supports controlled drug administration, reduces cross-contamination risks, and suits repeated treatments requiring reliable wearable delivery.

Fastest-Growing Segment – Hybrid Devices

Hybrid Devices account for approximately 18% of the On-Body Drug Delivery Devices Market, representing around USD 75.9 million in 2025, and are projected to record the fastest CAGR of 8.70% during 2026–2032. Hybrid configurations combine reusable electronic control modules with disposable drug reservoirs or fluidic components, reducing the amount of electronics discarded after each treatment cycle. This architecture supports repeated on-body administration while lowering per-use material requirements and improving the economic viability of long-term injectable therapies.

 

By Therapeutic Application: Diabetes Leads as Neurological Therapies Gain Ground

Leading Segment – Diabetes

Diabetes accounts for approximately 31% of the On-Body Drug Delivery Devices Market, representing around USD 130.7 million in 2025, and is projected to expand at a CAGR of 6.80% during 2026–2032. Diabetes remains the primary clinical application and testing ground for on-body drug delivery, particularly for automated and continuous subcutaneous insulin administration. Rising adoption of wearable insulin delivery systems, preference for convenient home-based therapy, and the need for precise dosing are strengthening the commercial position of this segment worldwide.

Fastest-Growing Segment – Neurological Disorders

Neurological Disorders account for approximately 8% of the On-Body Drug Delivery Devices Market, valued at around USD 33.7 million in 2025, and are projected to register the fastest CAGR of 8.60% during 2026–2032. Neurological conditions are encouraging the development of advanced on-body drug delivery platforms that provide precise, controlled, and continuous medication administration. Their ability to support targeted therapies and address physiological barriers, including the blood-brain barrier, is expanding their role in long-term neurological treatment and patient care.

 

By End User: Home Care Sets the Pace for Self-Administration

Leading and Fastest-Growing Segment – Home Care Settings

Home Care Settings account for approximately 49% of the On-Body Drug Delivery Devices Market, representing around USD 206.6 million in 2025, and are projected to record the fastest CAGR of 8.30% during 2026–2032. Home-based care enables patients to self-administer complex and large-volume therapies through on-body drug delivery systems, reducing dependence on routine clinic visits. Longer treatment cycles, preference for convenient self-administration, and increasing use of biologics for chronic conditions are expanding the role of on-body delivery platforms in home treatment.

 

By Geography: North America Leads While Asia-Pacific Accelerates Adoption

Leading Region – North America

North America holds approximately 42% of the global On-Body Drug Delivery Devices Market, equivalent to around USD 177.1 million in 2025, and is projected to expand at a CAGR of 6.70% during 2026–2032. The region’s leading position is supported by advanced healthcare infrastructure, wider adoption of home-based drug administration, and a large population managing chronic illnesses such as diabetes. Increasing use of biologics and preference for convenient, controlled medication delivery further strengthen on-body delivery adoption across the region.

Fastest-Growing Region – Asia-Pacific

Asia-Pacific represents approximately 23% of the On-Body Drug Delivery Devices Market, valued at around USD 97.0 million in 2025, and is projected to record the fastest regional CAGR of 8.80% during 2026–2032. Adoption across the region is accelerating as healthcare systems shift toward decentralized care and home-based treatment for chronic conditions. Expanding diabetes, cancer, and autoimmune disease treatment, alongside improving access to wearable drug administration technologies in China, Japan, South Korea, and India, is strengthening regional market activity.

 

How Are Commercial Scale, Large-Volume Delivery, and Smart Wearables Shaping Competition in the On-Body Drug Delivery Devices Market?

Insulet Corporation: Commercial Scale Built Around Tubeless Insulin Delivery

Insulet Corporation stands out as the leading commercial-scale company in the On-Body Drug Delivery Devices Market, supported by the large installed base of its wearable Omnipod insulin-delivery platform. The company reported more than 600,000 estimated global customers using Omnipod products in 2025, while its products were available across 25 countries. Omnipod 5 was also ranked as the No. 1 insulin pump for new pump users in both the United States and Europe during 2025. Insulet generated approximately USD 2.7 billion in total annual revenue in 2025, highlighting the commercial scale achieved by its wearable drug-delivery business.

Insulet's position is particularly strong because its disposable, tubeless Pod provides up to three days of continuous insulin delivery while being worn directly on the body. Omnipod 5 integrates with continuous glucose monitoring and automatically adjusts insulin administration, moving wearable delivery beyond a simple mechanical pump toward a connected treatment platform. The company's products were also available through more than 47,000 U.S. pharmacies in 2025, giving it a distribution footprint that remains difficult for newer wearable-device developers to match.

Other Important Companies and Their Market Roles:

• Enable Injections: A major specialist in large-volume wearable delivery through its enFuse platform, with more than 10,000 devices clinically tested in over 300 patients across 25 countries and over 8,000 commercial uses, giving the company an important position in biologic and high-volume subcutaneous administration.

• Stevanato Group: Developing the Vertiva on-body delivery system for 3 mL and 10 mL prefilled cartridges, combining a disposable injection pod with a reusable electronic controller and targeting biologics requiring flexible bolus or controlled dosing.

• West Pharmaceutical Services: Competes through the SmartDose 10 On-Body Delivery System, which can administer drug volumes of up to 10 mL and is designed for patient or caregiver use outside conventional healthcare facilities.

• Becton, Dickinson and Company (BD): Strengthens the market through its Libertas Wearable Injector, designed for 2–5 mL and 5–10 mL doses and biologics with viscosities of up to 50 cP; BD has completed more than 50 preclinical and clinical studies related to large-volume subcutaneous administration.

 

Analyst Commentary: Where Will the Next Wave of Value Emerge in Wearable Drug Delivery?

The On-Body Drug Delivery Devices Market is moving beyond basic wearable injection toward more flexible platforms capable of delivering larger-volume and higher-viscosity biologic therapies outside traditional clinical settings. The strongest commercial opportunities are emerging around home-based self-administration, reusable and hybrid device architectures, connected delivery systems, prefilled drug-device combinations, and wearable platforms designed for oncology, autoimmune diseases, diabetes, and other chronic therapies requiring controlled subcutaneous administration.

 

On-Body Drug Delivery Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 421.7 Million
Revenue Forecast in 2032	USD 687.9 Million
Overall Growth Rate	CAGR of 7.24% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Device Type, By Delivery Mechanism, By Device Configuration, By Therapeutic Application, By End User, By Geography
By Device Type	On-Body Injectors, Wearable Infusion Pumps, Patch-Based Delivery Devices
By Delivery Mechanism	Needle-Based Devices, Needle-Free Devices, Pump-Based Devices
By Device Configuration	Disposable Devices, Reusable Devices, Hybrid Devices
By Therapeutic Application	Diabetes, Oncology, Autoimmune Disorders, Cardiovascular Diseases, Neurological Disorders, Other Applications
By End User	Home Care Settings, Hospitals, Specialty Clinics, Ambulatory Care Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Growing preference for home-based drug administration, increasing use of biologics and large-volume/high-viscosity injectable therapies, rising demand for self-administration, expansion of wearable infusion systems, adoption of connected drug-delivery platforms, increasing chronic-disease treatment needs, and growing use of on-body delivery in oncology, autoimmune disorders, diabetes, and neurological therapies
Customization Option	Available upon request